Opinion: Now that the S&P 500 is looking overbought, watch what happens to this downtrend line that defines the bear market

The S&P 500 index has extended its gains, as we expected after last week’s breakout above resistance at 4170. The target was the declining 200-day moving average, which is currently at about 4325. The S&P SPX, +0.17% did “touch” that 200-day MA this week. Furthermore, the downtrend line that defines this bear market (blue line … Read more

Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion

Pfizer Inc. PFE -1.18% is in advanced talks to buy Global Blood Therapeutics Inc., GBT 33.03% the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline. Pfizer is aiming to seal a deal for GBT in the … Read more

Market Mayhem Triggers Deal-Making Drought – The Wall Street Journal

Market Mayhem Triggers Deal-Making DroughtThe Wall Street Journal

Elon Musk’s Twitter Fight Points to M&A Experts’ Big Fear: Collapsing Deals

While the Musk-Twitter fight has the market transfixed, a bigger issue for the M&A industry is the generally challenging backdrop for deals. With volatility continuing and interest rates rising, a slowdown is expected in the third quarter with the possibility of more transactions being pulled, a Bloomberg News survey of 16 M&A trading desks, fund … Read more

Biotech Stocks Are Flying. It’s Still a Bear Market.

Text size A net $ 1.1 billion poured into healthcare and biotech stocks in the week ended July 6, the second-highest amount this year. Dreamstime Biotech’s rally has not let up, but without any clear changes in the setup for the sector, it is hard to have confidence that the longer-term bear market in those … Read more

Merck Is Now in Advanced Talks to Buy Cancer Biotech Seagen for $ 40 Billion

Text size New Jersey-based Merck has a market value of more than $ 234 billion. Michael Vi / Dreamstime Merck & Co is an advanced talks to buy Seagen in a deal that could value the cancer biotech at $ 40 billion or more, according to a report Wednesday. The two companies are discussing a … Read more

Merck Is in Advanced Talks to Buy Seagen for Roughly $ 40 Billion or More

Merck & Co. is in advanced talks to acquire Seagen and is aiming to agree on a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $ 40 billion or more. The companies are discussing a price for Seagen … Read more

Merck Pushes Forward With Potential Deal For Seagen

Merck & Co. is pushing forward with a potential deal for biotech Seagen Inc., according to people familiar with the matter, in what would be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to buy Seagen, which would beef up the pharmaceutical giant’s … Read more